Takeda Pharmaceutical (TAK.US) plans to record a restructuring cost of 150 billion yen to drive cost reduction and efficiency through AI

This move marks the start of a comprehensive business restructuring phase for Japan's largest pharmaceutical company, aiming to increase efficiency and promote growth through cost reduction and the adoption of new technologies. In a statement released on Wednesday, the company said it expects restructuring costs to decrease after next year and plans to streamline corporate functions, projecting an annual total savings of over 200 billion yen each year.